Market for some cancer meds aims for $27.3B; GSK, Colgate settle toothpaste-label fight;

 @FiercePharma: Bayer, J&J's clot-fighter Xarelto wins key FDA nod for stroke prevention in AF pts-but with a warning. News | Follow @FiercePharma

> Small-molecule cancer drug sales are expected to grow to $27.3 billion by 2015, up from $20.3 billion in 2010, according to a new report from Visiongain. Item

> Amgen ($AMGN) shares jumped by almost 5% on news that it plans to buy back $5 billion of its shares over the next 30 days, for between $54 and $60 per share. Story

> GlaxoSmithKline ($GSK) and Colgate settled their fight over rights to the stylized blob of toothpaste known as a "nurdle," depicted on both companies' packaging. News

> Pfizer's ($PFE) bladder drug Toviaz met its primary endpoint in a study of urinary urgency during the night in patients with overactive bladder. Release

> Allergan ($AGN) plans a $12 million, 400-job research facility in New Jersey, after state officials offered a 10-year, $17 million grant. Article

> Express Scripts and Medco Health Solutions cut the termination fee on their proposed merger to $650 million. Report

Biotech News

 @FierceBiotech: Blockbuster breakup: Amylin buys out Lilly's exenatide rights in $1.6B deal. News | Follow @FierceBiotech

 @JohnCFierce: Key AZ/Targacept depression drug flunks first Phase III test. Item | Follow @JohnCFierce

 @RyanMFierce: Medidata (SaaS clinical trials software) reports profits up in 3Q, 33 new customers, $MDSO up 2.04%. Release | Follow @RyanMFierce

 @MaureenFierce: Nabi will explore strategic options after its anti-smoking vaccine NicVAX failed in a second Phase III trial. Article | Follow @MaureenFierce

> Key AZ/Targacept depression drug flunks first Phase III test. News

> Blockbuster breakup: Amylin buys out Lilly's exenatide rights in $1.6B deal. Story

> Biotech's Biggest Spenders 2011. Report

Biotech Research News

> Eliminating 'senescent' cells in mice delayed age-related ailments. News

> Stem cell therapy for Parkinson's works wells in two animal models. Story

> Scripps breakthrough unlocks the potential of a promising cancer drug class. More

Manufacturing News

> Plant check reveals Genentech report flaw repeat. Article

> Pharma recalls up 54% in Q3. Item

> MedImmune cell-culture plant named facility of the year. News

And Finally... U.S. pediatricians write 10 million unnecessary antibiotic prescriptions a year, a new study found. Story

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.